Eletriptan: A review of its use in the acute treatment of migraine

Drugs

Volumn 66, Issue 8, 2006, Pages 1129-1149

  McCormack, Paul L ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; CYTOCHROME P450 3A4; ELETRIPTAN; ERGOTAMINE; ERYTHROMYCIN; FLUCONAZOLE; KETOCONAZOLE; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SUMATRIPTAN; VERAPAMIL; ZOLMITRIPTAN;

AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HEMODYNAMICS; HUMAN; MIGRAINE; NAUSEA; NEUROGENIC INFLAMMATION; NONHUMAN; QUALITY OF LIFE; RECEPTOR BINDING; REVIEW; SOMNOLENCE; TABLET FORMULATION; VASOCONSTRICTION;

ANIMALS; HUMANS; MIGRAINE DISORDERS; PYRROLIDINES; SEROTONIN AGONISTS; TRYPTAMINES;

ANIMALIA;

EID: 33745472658     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666080-00010     Document Type: Review

References (100)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 Jul-Aug; 41 (7): 646-57
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002; 346 (4): 257-70
3. Diamond S, Wenzel R. Practical approaches to migraine management. CNS Drugs 2002; 16 (6): 385-403
4. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000; 62 (5): 509-25
5. Dodick DW, Silberstein S, Dahlof CGH. Is there a preferred triptan? Headache 2002 Jan; 42 (1): 1-7
6. 1B/1D agonists in acute migraine with special reference to second generation agents. Acta Neurol Belg 1999; 99: 85-95
7. Jhee SS, Shiovitz T, Crawford AW, et al. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001; 40 (3): 189-205
8. Bardsley-Elliot A, Noble S. Eletriptan. CNS Drugs 1999 Oct; 12 (4): 325-33
9. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002 Jul; 59 (7): 1084-8
10. Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833-42
11. Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia 2000; 20 Suppl. 1: 2-9
12. Johnson KW, Schaus JM, Durkin MM, et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997 Jul; 8 (9-10): 2237-40
13. 1D receptors. Eur J Pharmacol 1999; 368: 259-68
14. 1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 212-9
15. 1B/1D receptor agonist. Eur J Pharmacol 2000 Jun 9; 398 (1): 73-81
16. MaassenVanDenBrink A, van den Broek RW, de Vries R, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000 Nov 28; 55 (10): 1524-30
17. 1B/1D-receptor agonist. Clin Pharmacol Ther 1999 Jul; 66 (1): 85-90
18. 1D-like" receptor [abstract no. 77]. Cephalalgia 1996; 16: 386
19. Knyihar-Csillik E, Tajti J, Csillik AE, et al. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 2000 Nov; 12 (11): 3991-4002
20. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990 Aug; 28 (2): 183-7
21. Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat. Pain 1999; 82: 15-22
22. Lambert GA, Boers PM, Hoskin KL, et al. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 2002 Oct 25; 953 (1-2): 181-8
23. Johnson DE, Rollema H, Schmidt AW, et al. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol 2001 Aug 17; 425 (3): 203-10
24. 1B/1D receptor agonists [abstract]. Headache Q 2001; 12 (1): 45
25. Polli J, Humphreys J, Wring S, et al. Eletriptan, but not sumatriptan, is a substrate for P-glycoprotein [abstract no. 377]. Cephalalgia 2000; 20: 417
26. Evans DC, O'Connor D, Lake BG, et al. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003 Jul; 31 (7): 861-9
27. Milton KA, Scott NR, Allen MJ, et al. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT1B/1D agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002 May; 42 (5): 528-39
28. Johnson BF, Shah A, Law G. The absorption kinetics of eletriptan in migraineurs [abstract]. Headache 1997 May; 37 (5): 315
29. 1D-like' receptor partial agonist [abstract]. Headache 1997 May; 37 (5): 324
30. Rance DJ, Horspool K, James G, et al. The absorption potential of eletriptan (UK-116,044) and sumatriptan [abstract no. 80]. Cephalalgia 1996 Aug; 16 (5): 387
31. 1D-like' receptor agonist [abstract no. 76]. Cephalalgia 1996 Aug; 16 (5): 385
32. Shah AK, Laboy-Goral L, Morse TA, et al. The pharmacokinetics of oral eletriptan, and its excretion into breast milk in normal, healthy, nursing women [abstract no. P.60]. Cephalalgia 1998 Jul; 18 (6): 412
33. Morgan P, Rance DJ, James G, et al. An in vitro-in vivo correlation of eletriptan pharmacokinetics and metabolism in rat, dog, and human [abstract]. Headache 1997 May; 37 (5): 324
34. Hyland R, Jones BC, McCleverty P, et al. In vitro metabolism of eletriptan in human liver microsomes [abstract no. P.34]. Cephalalgia 1998; 18: 404
35. Milton KA, Buchanan TJ, Haug-Pihale G, et al. The pharmacokinetics, safety, and tolerability of oral eletriptan in subjects with impaired hepatic function [abstract no. P.58]. Cephalalgia 1998 Jul; 18 (6): 411-2
36. Milton KA, Tan E, Boyce MJ, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of oral eletriptan in young and elderly, male and female subjects [abstract no. P.36]. Cephalalgia 1998 Jul; 18 (6): 405
37. Alderman JA, Hettiarachchi J, Sikes C. The metabolism of eletriptan: clinical safety in the acute treatment of migraine [abstract no. S32.002]. Neurology 2003 Mar 11; 60 Suppl. 1: A253-4
38. Milton KA, Tan L, Love R. The pharmacokinetic and pharmacodynamic interactions of oral eletriptan and propranolol in healthy volunteers [abstract no. P.59]. Cephalalgia 1998 Jul; 18 (6): 412
39. Shah AK, Harris SC, Greenhalgh C, et al. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 2002 May; 42 (5): 520-7
40. Grujich NN, Gawel MJ. Eletriptan. Expert Opin Investig Drugs 2001 Oct; 10 (10): 1869-74
41. Pfizer Inc. Relpax. (eletriptan hydrobromide) tablets, US prescribing information [online]. Available from URL: http://www.pfizer.com [Accessed 2006 Apr 27]
42. Shah AK, Laboy-Goral L, Scott N, et al. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. J Clin Pharmacol 2001 Dec; 41 (12): 1339-44
43. Pfizer Limited. Relpax - 20 mg and 40 mg: UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2006 Apr 27]
44. Pichard-Garcia L, Hyland R, Baulieu J, et al. Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. Drug Metab Dispos 2000; 28 (1): 51-7
45. Färkkilä M, Eletriptan Steering Committee. A dose-finding study of eletriptan (UK-116,044) (5-30 mg) for the acute treatment of migraine [abstract no. 81]. Cephalalgia 1996; 16: 387-8
46. Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003 Mar; 43 (3): 202-13
47. Fukuuchi Y, Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002 Jul; 22 (6): 416-23
48. Stark R, Dahlof C, Haughie S, et al. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002 Feb; 22 (1): 23-32
49. F̈arkkilä M, Olesen J, Dahlöf C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003; 23: 463-71
50. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000 Jan 11; 54 (1): 156-63
51. Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003 Mar; 43 (3): 214-22
52. Sandrini G, Färkkilä M, Burgess G, et al. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002 Oct 22; 59 (8): 1210-7
53. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47 (2): 99-107
54. Garcia-Ramos G, MacGregor EA, Hilliard B, et al. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003 Nov; 23 (9): 869-76
55. Steiner TJ, Diener HC, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003 Dec; 23 (10): 942-52
56. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765-86
57. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for the treatment of migraine (draft) [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 May 23]
58. Brandes JL, Kudrow D, Cady R, et al. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005 Sep; 25 (9): 735-42
59. Milton KA, Kleinermans D, Scott N, et al. The bioequivalence of standard sumatriptan tablets and two encapsulated forms of sumatriptan. Int J Pharm Med 2001; 15 (1): 21-6
60. Spierings EL. Electriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan [letter]. Neurology 2000 Sep 12; 55 (5): 735; author reply 736
61. Deleu D, Hanssens Y. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study [letter]. Neurology 2003 Apr 8; 60 (7): 1221-2; author reply 1221-2
62. Fuseau E, Petricoul O, Sabin A, et al. Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clin Ther 2001; 23 (2): 242-51
63. Sikes C, Alderman J, Emir B, et al. Encapsulation of sumatriptan tablets does not alter their bioavailability or dissolution characteristics [abstract no. S154]. Headache 2003 May; 43 (5): 581-2
64. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain - results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 2005 Sep; 25 (9): 715-25
65. Sandrini G, Färkkilä M, Forster E. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Reply from the authors [letter]. Neurology 2003 Apr 8; 60 (7): 1222
66. GlaxoSmithKline. Imitrex® (sumatriptan succinate) tablets: prescribing information [online]. Available from URL: http://us.gsk.com/ products/assets/us_imitrex_tablets.pdf [Accessed 2006 Apr 27]
67. Rasmussen S, Olesen J, Färkkilä M, et al. Efficacy of eletriptan in acute migraine treatment of patients who discontinued oral sumatriptan: a randomized, placebo-controlled study [abstract no. F63]. Headache 2002 May; 42 (5): 398
68. Diener HC, Ryan R, Sun W, et al. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol 2004 Feb; 11 (2): 125-34
69. Vollono C, Capuano A, Mei D, et al. Multiple attack study on the available triptans in Italy versus placebo. Eur J Neurol 2005 Jul; 12 (7): 557-63
70. Lainez M, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006 Mar; 26 (3): 246-56
71. Schoenen J, Pascual J, Rasmussen S, et al. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur J Neurol 2005 Feb; 12 (2): 108-17
72. Funk Orsini PA, Miceli RJ. Improvement in migraine-specific quality of life with eletriptan (Relpax™) vs Cafergot® [abstract no. P2-K61]. Cephalalgia 2001 May; 21: 431-2
73. Funk Orsini PA, Miceli RJ. Comparison of the impact of eletriptan (Relpax™) and sumatriptan on migraine-specific quality of life [abstract no. P2-K62]. Cephalalgia 2001 May; 21: 432
74. Badia X, Slof J, Magaz S, et al. Cost-efficacy of oral triptans in the treatment of acute migraine in Spain [abstract no. S111]. Headache 2003 May; 43: 563-4
75. Weis KA. Application of cost-effectiveness analysis to six triptans using data from a published meta-analysis [abstract no. S124]. Headache 2003 May; 43: 569
76. Weis KA. Cost per successfully treated patient as measure of effectiveness in comparing eletriptan to sumatriptan [abstract no. PNP19]. Value Health 2003 May-Jun; 6 (3): 278
77. Dugar A, Healey PJ, Weis K. Triptans in the acute treatment of migraine: cost-effectiveness analysis based on number needed to treat and doses needed to treat [abstract no. PNL8]. Value Health 2004; 7 (3): 290.
78. Plus poster presented at the 9th International Meeting of the International Society for Pharmacoeconomics and Outcomes; 2004 May 16-19; Arlington (VA)
79. Wells N, Hettiarachchi J, Drummond M, et al. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health 2003 Jul; 6 (4): 438-47
80. Gracia-Naya M, Rejas Gutiérrez J, Latorre Jiménez A, et al. Economic evaluation of acute migraine attack treatment with triptans in Spain [in Spanish]. Neurologia 2005 Apr; 20 (3): 121-32
81. Perfetto EM, Weis KA, Mullins CD, et al. An economic evaluation of triptan products for migraine. Value Health 2005 Nov-Dec; 8 (6): 647-55
82. Belsey JD. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 2004 May; 20 (5): 659-69
83. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 Nov 17; 358 (9294): 1668-75
84. Wells NEJ, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2000 Dec; 18 (6): 557-66
85. Wells NEJ. The effectiveness of oral eletriptan (20-80 mg) at reducing the time loss associated with an acute migraine attack [abstract no. P05.138]. Neurology 2000 Apr 11; 54 (7 Suppl. 3): 382
86. Wells NEJ. Comparison of the effectiveness of eletriptan, sumatriptan and Cafergot® in reducing the time loss associated with migraine attacks. J Drug Assess 2001; 4: 265-74
87. McKenzie I, Pitman V. Safety, tolerability, and efficacy of eletriptan (40 mg - 80 mg) for long-term treatment of migraine [abstract no. P 3054]. Eur J Neurol 2000 Nov; 7 Suppl. 3: 118
88. British National Formulary (BNF 51). Eletriptan [online]. Available from URL: http://www.bnf.org/bnf [Accessed 2006 Apr 27]
89. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004 Jan; 55 (1): 27-36
90. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002 Jan; 42 (1): 28-31
91. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs 2004; 18 (6): 337-42
92. Krusz JC. Eletriptan and migraine pre-emption [abstract no. PC.20]. Cephalalgia 2004 Sep; 24 (9): 796-7
93. Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004 Oct; 11 (10): 671-7
94. Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004 Feb 24; 62 (4): 563-8
95. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002 Oct; 22 (8): 633-58. Erratum in Cephalalgia 2003 Feb; 23 (1): 71
96. Oldman AD, Smith LA, McQuay HJ, et al. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002 Jun; 97 (3): 247-57
97. Roon KI, Lipton RB, Goadsby PJ, et al. Efficacy of six oral triptans at 1 h post-dose: a meta-analysis [abstract no. P2-K1]. Cephalalgia 2001 May; 21 (4): 405
98. Mathew NT. Comparison of therapeutic gains over sumatriptan for eletriptan, naratriptan, rizatriptan and zolmitriptan: a review of six clinical studies [abstract no. P2-K6]. Cephalalgia 2001 May; 21 (4): 407
99. Tepper SJ, Allen CP, Vandonnael K. Therapeutic benefit of rizatriptan compared with eletriptan [abstract]. Headache Q 2001; 12 (3): 197
100. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001 Oct; 10 (10): 1831-45